Keurig Dr Pepper Inc. KDP

Zacks Investment Research 12 nov

Keurig Dr Pepper (KDP) secured new Dr Pepper fountain distribution at Jersey Mike's, strengthening its away-from-home presence. Dr Pepper achieved double-digit Q3 net sales growth and is the most widely available fountain beverage across major U.S. foodservice chains. Dr Pepper Zero delivered 25% retail sales growth and surpassed $1 billion in annualized retail sales. KDP shares rallied 22.9% in three months and trade at a forward P/E of 15.35, below the industry average of 20.79.

Zacks Investment Research 12 nov

Coca-Cola (KO) reached a 52-week high of $97.83 with a 39.6% YTD gain, driven by strong Q3 results including 7% organic revenue growth and 11% EPS growth. However, the stock's 27.8X forward P/E valuation is significantly higher than peers, suggesting it is overvalued at current levels. Analysts recommend holding for existing shareholders while prospective investors should wait for a better entry point.

GlobeNewswire Inc. 10 nov

The US coffee market is projected to grow from USD 24.98 billion in 2026 to USD 32.23 billion by 2032, with a CAGR of 4.32%. Specialty coffee is the fastest-growing segment at 6.78% CAGR, driven by premiumization and functional coffee options. Market growth is supported by packaged coffee affordability, specialty adoption, app-based ordering, and premium prepared-coffee occasions.

Zacks Investment Research 10 nov

Keurig Dr Pepper (KDP) is highlighted as a stock to watch for momentum investors, holding a #3 (Hold) Zacks Rank with a B VGM Score. The stock has gained 12.8% over the past four weeks, and three analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $2.31 per share.

Zacks Investment Research 5 nov

PepsiCo trades at a valuation discount (16.6X forward P/E vs. 20.4X five-year median) but faces headwinds that make waiting prudent. The company cut 2026 earnings growth guidance to 2.5-3.5% and projects only 2.5% growth for 2027. While international operations show strength with 8% organic revenue growth, North American weakness and margin pressures limit the investment case. Analysts recommend waiting for stronger earnings revisions or evidence of margin recovery.